Abstract:The design of an aqueous formulation for acidic fibroblast growth factor (aFGF) requires an understanding of the type of compounds that can either directly or indirectly stabilize the protein. To this end, spectrophotometric turbidity measurements were initially employed to screen the ability of polyanionic ligands, less specific compounds, and variations in solution conditions (temperature and pH) to stabilize aFGF against heat-induced aggregation. It was found that in addition to the well-known protection of aFGF by heparin, a surprisingly wide variety of polyanions (including small sulfated and phosphorylated compounds) also stabilizes aFGF. These polyanionic ligands are capable of raising the temperature at which the protein unfolds by 15-30 degrees C. Many commonly used excipients were also observed to stabilize aFGF in both the presence and the absence of heparin. High concentrations of some of these less specific agents are also able to increase the temperature of aFGF thermal unfolding by as much as 6-12 degrees C as shown by circular dichroism and differential scanning calorimetry. Other compounds were found which protect the chemically labile cysteine residues of aFGF from oxidation. Aqueous formulations of aFGF were thus designed to contain both a polyanionic ligand that enhances structural integrity by binding to the protein and chelating agents (e.g., EDTA) to prevent metal ion-catalyzed oxidation of cysteine residues. While room-temperature storage (30 degrees C) leads to rapid inactivation of aFGF in physiological buffer alone, several of these aFGF formulations are stable in vitro for at least 3 months at 30 degrees C. Three aFGF topical formulations were examined in an impaired diabetic mouse model and were found to be equally capable of accelerating wound healing.

Quality Assessment and Stability Test of Basic Fibroblast Growth Factor Nasal Spray

Preparation of Chitosan Scaffolds Controlling-released bFGF and its Effect on Cell Culture

Gelatin Nanostructured Lipid Carriers-Mediated Intranasal Delivery of Basic Fibroblast Growth Factor Enhances Functional Recovery in Hemiparkinsonian Rats

Effect of Absorption Enhancers on Nasal Delivery of Basic Fibroblast Growth Factor

Evaluation on the Conditions Influencing the Chemical Stability of Recombinant Human Granulocyte Colony Stimulating Factor

Clinical Effects of FuFang XuanJu Capsule on Quality of Sperm and Reproductive Hormone in Rats with Infertility

Studies on the Stability of Mometasone Furoate in Situ Gel

Preparation and Ciliotoxicity of Interferon Α-2B Nasal Spray

Preparation and Quality Control of Mometasone Furoate Gel

New RP-HPLC Method for Precise Determination of Chemical Stability of Rhg-Csf Products

In Vivo Validation of Biological Responses of Bfgf Released from Microspheres Formulated by Blending Poly-Lactide-co-Glycolide and Poly(ethylene Glycol)-Grafted-chitosan in Hamster Cheek Pouch Microcirculatory Models

Formulation design of acidic fibroblast growth factor

Optimization of lyoprotectant for recombinant human acidic fibroblast growth factor by response surface methodology

In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions

Stability of Salmon Calcitonin Nasal Spray Under Simulated Transportation and Usage Condition

Study of Preparation and Quality Standards of Throat Spray

In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate.

[The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters]

Preparation and Evaluation of Intranasal in Situ Gel of Bupleuri Radix Volatile Oil and Baicalin

Preparation and in vitro characterization of thermosensitive and mucoadhesive hydrogels for nasal delivery of phenylephrine hydrochloride

Preparation and quality control of compound fusidic acid ophthalmic emulsion